ALPHA.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:35):

Stats
今日成交量	329 806
平均成交量	40 149.00
市值	60 019.00
EPS	€0 ( 2024-04-19 )
下一个收益日期	( €0 ) 2024-05-07
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	0
ATR14	€0.00300 (3.05%)

音量相关性

長: -0.19 (neutral)

短: -0.52 (weak negative)

Signal:(45.963) Neutral

Pharnext SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Pharnext SA 相关性 - 货币/商品

-0.40
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.55
( weak negative )

Pharnext SA 财务报表

Annual	2022
营收:	€558.00
毛利润:	€2.26M (404 643.19 %)
EPS:	€-8.32

FY	2022
营收:	€558.00
毛利润:	€2.26M (404 643.19 %)
EPS:	€-8.32

FY	2021
营收:	€84 785.00
毛利润:	€0.00 (0.00 %)
EPS:	€-5 033.08

FY	2020
营收:	€39 830.00
毛利润:	€-284 720 (-714.84 %)
EPS:	€-5 920.66

Financial Reports:

No articles found.

Pharnext SA

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

实时更新： Pharnext SA [ALPHA.PA]

Upcoming Earnings Alert